Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
203 - Hello, i am looking for an official definition of on-label as it relates to conversations that a pharma rep can have with a HCP. Although all material need to be PAAB-approved, verbal exchange in the office can touch on latest data publicly available, such as posters, conference reports, etc. If referring to approved dosage, patient population and condition, can the reps discuss this with physicians in an effort to have robust clinical and scientific discussions... best regards
-
"On-label" is equivalent to "consistent with the Terms of Marketing Authorization (label, product monograph, product license) that has been approved by Health Canada." See PAAB Code s3.1. Verbal discussions by sales reps are covered by the Food & Drugs Act and Regulations. Therefore, a representative can talk about new studies that are not part of the product monograph if the content is consistent with the indications, dosing, and degree of efficacy and safety stated in the Product Monograph. Rule of thumb - if the PAAB would not approve the information in a print piece, the rep should not be promoting that information verbally. Also see Innovative Medicines Canada Code of Ethical Practices
